Compare Cassava Sciences Inc (FLNA) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Materials Select Sector SPDR Fund — how do they compare? Cassava Sciences Inc trades at $0.82 (market cap $39.40M), while Materials Select Sector SPDR Fund trades at $49.34 (market cap $7.73B). The key difference: Materials Select Sector SPDR Fund is far larger — about 196.2× Cassava Sciences Inc's market cap, and Materials Select Sector SPDR Fund is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cassava Sciences Inc for 37 Days and Materials Select Sector SPDR Fund for 70 Days on average.
| FLNA | XLB | |
|---|---|---|
Market Cap | $39.40M | $7.73B |
Volume | 759,018 | 13,681,146 |
Sector | Health | — |
52-Week High | $4.64 | $53.67 |
52-Week Low | $0.68 | $42.23 |
Typical Hold Time | 37 Days | 70 Days |
Enterprise Value | -$43.28M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $0.8157, down 6.77% today, with a bearish technical signal from moving averages. The company shows improving quarterly EPS trends, beating expectations in recent quarters, though it remains unprofitable with negative ROE and ROA. Recent FDA clearance for its epilepsy drug trial provides a positive catalyst. Analyst sentiment is bullish with 67% buy ratings.
The outlook hinges on clinical progress; upside exists if Phase 2a trials succeed, but high cash burn and lack of revenue pose significant risks. Investors should weigh the strong analyst support against the company's financial challenges and binary clinical outcomes.
XLB, the Materials Select Sector SPDR ETF, trades at $48.98, down 1.51% on the day, with a bearish technical signal driven by moving averages and key indicators like ADX signaling strong selling pressure. The ETF's portfolio is heavily concentrated in chemicals (49% of assets), and recent news highlights sector volatility amid broader market challenges outside of tech. A dividend of $0.23 is scheduled for September 2026, but financial ratios are currently unavailable.
The outlook for XLB is cautious due to technical weakness and sector cyclicality, though long-term infrastructure and AI-related demand offer potential upside. Risks include economic sensitivity and high concentration, while investor sentiment remains mixed with some analysts seeing value in materials as an AI-resistant play.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
